Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giuseppe Guardascione
Observed names:
G. Guardascione,
Guardascione, Giuseppe
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
ORCID:
0000-0003-4272-7948
Observed ORCID:
0000-0003-4272-7948
OpenAlex ID:
A5088633559
CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment
2021
·
Sara Santagata
, Caterina Ieranò
, et al.
·
Frontiers in Oncology
·
117
PDF
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
2022
·
Caterina Ieranò
, Dario Righelli
, et al.
·
Journal for ImmunoTherapy of Cancer
·
74
PDF
CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients
2022
·
Crescenzo D’Alterio
, Alessandro Giardino
, et al.
·
Cells
·
16
PDF
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization
2024
·
Luigi Portella
, Giulia Bertolini
, et al.
·
Heliyon
·
9
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
·
Clinical Cancer Research
·
7
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells
2026
·
Federica Auletta
, Caterina Ieranò
, et al.
·
Cell Death Discovery
·
1
PDF
Abstract 6815: CXCL12-loaded-hydrogel (CLG) in vivo modifies lung metastatic niche toward an immunoactive microenvironment reducing lung metastasis development
2024
·
Giuseppe Guardascione
, Luigi Portella
, et al.
·
Cancer Research
·
1
CXCR4+ circulating tumor cells (CTCs) accumulate in subcutaneous, immune suppressive, CXCL12-loaded-hydrogel
2026
·
Luigi Portella
, Dario Guido Di Febbraro
, et al.
·
Materials Today Bio
Supplementary Figure S10 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Data from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S12 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S4 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
PDF
Supplementary Figure S6 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S2 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S11 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S3 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Tables S1-S12 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S8 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S13 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
PDF
Supplementary Figure S9 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
PDF
Supplementary Figure S7 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S5 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
Supplementary Figure S1 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024
·
Sara Santagata
, Anna Maria Trotta
, et al.
PDF
CXCL12 expression predicts survival in Radically Resected (R0) primary pancreatic adenocarcinoma
2022
·
D'Alterio, Crescenzo
, Giardino, Alessandro
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
1796P CXCL12-loaded-hydrogel (CLG) based 'pseudo niche': A new device for CTCs capturing and characterization
2021
·
L. Portella
, G. Guardascione
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
28
Citation count:
225
H-index:
5
I10-index:
3
Year
Topic
Type